What is the usage and dosage of teclistamab?

Teritolumab (Teclistamab) is a bispecific TT cell-directed antibody mainly used to treat relapsed or refractory multiple myeloma. It works by simultaneously binding to CD3 (on the surface of T cells) and BCMA (on the surface of myeloma cells), thereby guiding T cells to recognize and kill tumor cells. Due to its special mechanism of action, the use of teritusumab is complicated and must be performed in strict accordance with regulations in experienced medical institutions.

The recommended administration method of teritusumab is subcutaneous injection with ** step-up dosage (step-up dosing)** dosing strategy to reduce the risk of adverse reactions such as cytokine release syndrome (CRS). The common administration steps are: an initial small dose is given on day 1, an intermediate dose is given on day 4, and the target therapeutic dose is given on day 7; then the maintenance phase is entered, with subcutaneous injections every week or every two weeks until the disease progresses or the patient cannot tolerate it.

Before use, patients usually need to undergo relevant screening and pretreatment, such as prophylactic administration of antipyretics, antihistamines, and corticosteroids to reduce the risk of immune-related adverse reactions. A certain period of observation is required after injection in order to promptly handle possible adverse reactions, especially CRSand nervous system toxicity. Doctors will flexibly adjust the dosage regimen based on the patient's weight, condition, tolerance, and treatment response.

In short, the usage and dosage of teritusumab must strictly follow professional guidance and should not be used by oneself. Treatment must be monitored by an experienced oncologist or hematologist and conducted in a medical facility equipped to handle severe immune reactions. Proper use not only improves efficacy, but also helps minimize risks during treatment. Patients should fully understand the characteristics of the drug before receiving treatment and actively cooperate with doctors for monitoring and follow-up.

Reference materials:https://www.tecvayli.com/